News
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval